PE20140871A1 - COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA - Google Patents

COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA

Info

Publication number
PE20140871A1
PE20140871A1 PE2013001482A PE2013001482A PE20140871A1 PE 20140871 A1 PE20140871 A1 PE 20140871A1 PE 2013001482 A PE2013001482 A PE 2013001482A PE 2013001482 A PE2013001482 A PE 2013001482A PE 20140871 A1 PE20140871 A1 PE 20140871A1
Authority
PE
Peru
Prior art keywords
bovine
vaccine
virus
compositions
methods
Prior art date
Application number
PE2013001482A
Other languages
English (en)
Inventor
Dale Wade Weise
James Robert Harris
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45531546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140871(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20140871A1 publication Critical patent/PE20140871A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

REFERIDO A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE UN VIRUS DE DIARREA VIRAL BOVINA TIPO 1b (BVDV-1b) VIVO, MODIFICADO Y UN PORTADOR VETERINARIO ACEPTABLE. ADEMAS LA COMPOSICION COMPRENDE UN VIRUS RINOTRAQUEITIS BOVINA INFECCIOSO (IBRV), UN VIRUS SINCITIAL RESPIRATORIO BOVINO (BRSV), UN VIRUS DEL HERPES BOVINO (BHV-1), ENTRE OTROS; Y AL MENOS UN ANTIGENO ADICIONAL INACTIVADO. SE REFIERE TAMBIEN A UNA VACUNA QUE COMPRENDE LA COMPOSICION INMUNOGENICA Y UN ADYUVANTE. DICHAS COMPOSICIONES SON UTILES PARA EL TRATAMIENTO DE INFECCION VIRAL O MICROBIANA EN GANADO MAMIFERO
PE2013001482A 2010-12-27 2011-12-21 COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA PE20140871A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061427361P 2010-12-27 2010-12-27

Publications (1)

Publication Number Publication Date
PE20140871A1 true PE20140871A1 (es) 2014-07-19

Family

ID=45531546

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001482A PE20140871A1 (es) 2010-12-27 2011-12-21 COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA

Country Status (19)

Country Link
US (1) US20130280294A1 (es)
EP (1) EP2658570B1 (es)
JP (1) JP6053036B2 (es)
KR (1) KR101554080B1 (es)
CN (1) CN103347534B (es)
AU (1) AU2011352800B2 (es)
BR (1) BR112013016503A2 (es)
CA (1) CA2822825C (es)
CL (1) CL2013001877A1 (es)
CO (1) CO6761399A2 (es)
ES (1) ES2709190T3 (es)
MX (1) MX351380B (es)
NZ (1) NZ611531A (es)
PE (1) PE20140871A1 (es)
PL (1) PL2658570T3 (es)
PT (1) PT2658570T (es)
RU (1) RU2595873C2 (es)
SG (1) SG191396A1 (es)
WO (1) WO2012092053A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084358A1 (es) * 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN107970443A (zh) * 2016-12-28 2018-05-01 浙江海隆生物科技有限公司 牛病毒性腹泻病毒e2蛋白亚单位疫苗组合物及其制备方法和应用
CN107823639B (zh) * 2017-11-10 2020-10-02 齐鲁动物保健品有限公司 牛病毒性腹泻病毒灭活疫苗及其制备方法
KR101960016B1 (ko) * 2018-04-09 2019-07-15 전북대학교 산학협력단 호흡기 질병의 원인체를 검출하기 위한 조성물 및 이를 이용한 방법
KR101960017B1 (ko) * 2018-04-09 2019-07-15 전북대학교 산학협력단 호흡기 질병의 원인체를 검출하기 위한 조성물 및 이를 이용한 방법
KR102101208B1 (ko) 2019-10-16 2020-04-17 주식회사 모투스 비산먼지 제거 기능이 있는 런닝머신
CN112034169A (zh) * 2020-08-27 2020-12-04 华威特（江苏）生物制药有限公司 用于检测牛病毒性腹泻病毒1型的直接免疫荧光试剂及其试剂盒
CN113207733B (zh) * 2021-05-28 2022-09-09 杨国胜 一种具有麻醉作用的畜牧用耳标
CN114634996A (zh) * 2022-02-28 2022-06-17 广东海大畜牧兽医研究院有限公司 用于检测牛呼吸道疾病的引物探针组合、试剂盒及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FR2596761B1 (fr) 1986-04-08 1988-05-20 Commissariat Energie Atomique Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
US5491225A (en) 1991-12-19 1996-02-13 Hoffmann-La Roche Inc. PCR primers for detection of legionella species and methods for controlling visual intensity in hybridization assays
ES2429401T3 (es) * 1994-05-10 2013-11-14 Boehringer Ingelheim Vetmedica, Inc. Vacuna viva modificada contra el BRSV, mejorada
US7563449B2 (en) * 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
US7361357B2 (en) * 2003-07-29 2008-04-22 Pfizer Inc. Safe mutant viral vaccines
EP1727562B1 (en) * 2004-03-17 2008-06-18 Pharmacia & Upjohn Company LLC Method of vaccination against testicular bvdv infection
CA2616826A1 (en) * 2005-08-04 2007-02-15 Wyeth Stabilizers for veterinary vaccines
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods

Also Published As

Publication number Publication date
WO2012092053A1 (en) 2012-07-05
PL2658570T3 (pl) 2019-05-31
MX2013007584A (es) 2013-10-17
JP2014502619A (ja) 2014-02-03
US20130280294A1 (en) 2013-10-24
KR101554080B1 (ko) 2015-09-17
MX351380B (es) 2017-10-12
NZ611531A (en) 2015-04-24
JP6053036B2 (ja) 2016-12-27
RU2013128921A (ru) 2015-02-10
CO6761399A2 (es) 2013-09-30
CA2822825C (en) 2016-02-09
CN103347534B (zh) 2018-09-11
SG191396A1 (en) 2013-08-30
KR20130109220A (ko) 2013-10-07
PT2658570T (pt) 2019-02-08
CN103347534A (zh) 2013-10-09
CA2822825A1 (en) 2012-07-05
AU2011352800B2 (en) 2015-09-03
EP2658570B1 (en) 2018-11-28
RU2595873C2 (ru) 2016-08-27
ES2709190T3 (es) 2019-04-15
EP2658570A1 (en) 2013-11-06
BR112013016503A2 (pt) 2018-05-22
CL2013001877A1 (es) 2014-03-07
AU2011352800A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
MX349294B (es) Formulaciones virales liofilizadas.
UY32274A (es) Pestivirus quimericos
MX2013006170A (es) Formulaciones virales liquidas.
WO2013104995A3 (en) Compositions and methods for treating viral infections
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
MX2020004811A (es) Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR103427A1 (es) Vacuna contra la fiebre aftosa
AR072976A1 (es) Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
MX2016001695A (es) Composiciones inmunogenas de combinacion.
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CO6700818A2 (es) Vectores de parapoxvirus
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
AR085800A1 (es) Vacuna de rinitis equina
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
RU2010120755A (ru) Вакцина, ассоциированная против парвовирусной, реовирусной, герпесвирусной типа i инфекций и вирусной диареи - болезни слизистых оболочек крупного рогатого скота, инактивированная эмульсионная
CL2023002187A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino
AR084225A1 (es) Composiciones y metodos para vacunar ganado vacuno
CL2023001826A1 (es) Eliminación genómica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables
BR102012021810A2 (pt) Xantana como adjuvante em vacina de subunidade recombinante

Legal Events

Date Code Title Description
FG Grant, registration